206 related articles for article (PubMed ID: 16802855)
1. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
Kokki H; Rasanen I; Lasalmi M; Lehtola S; Ranta VP; Vanamo K; Ojanperä I
Clin Pharmacokinet; 2006; 45(7):745-54. PubMed ID: 16802855
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
Kokki H; Rasanen I; Reinikainen M; Suhonen P; Vanamo K; Ojanperä I
Clin Pharmacokinet; 2004; 43(9):613-22. PubMed ID: 15217304
[TBL] [Abstract][Full Text] [Related]
3. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.
Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US
Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
5. Effect of pH on sublingual absorption of oxycodone hydrochloride.
Al-Ghananeem AM; Malkawi AH; Crooks PA
AAPS PharmSciTech; 2006 Mar; 7(1):E23. PubMed ID: 16584154
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan S; Edwards SR; Wyse BD; Smith MT
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
[TBL] [Abstract][Full Text] [Related]
7. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
Neuvonen M; Neuvonen PJ
Ther Drug Monit; 2008 Jun; 30(3):333-40. PubMed ID: 18520605
[TBL] [Abstract][Full Text] [Related]
8. Grapefruit juice enhances the exposure to oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
[TBL] [Abstract][Full Text] [Related]
9. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.
Darwish M; Kirby M; Jiang JG; Tracewell W; Robertson P
Clin Drug Investig; 2008; 28(1):1-7. PubMed ID: 18081355
[TBL] [Abstract][Full Text] [Related]
11. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
Pöyhiä R; Seppälä T; Olkkola KT; Kalso E
Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934
[TBL] [Abstract][Full Text] [Related]
14. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
15. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
Edwards SR; Smith MT
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
[TBL] [Abstract][Full Text] [Related]
16. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
Kirvela M; Lindgren L; Seppala T; Olkkola KT
J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
[TBL] [Abstract][Full Text] [Related]
18. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.
Pantano F; Brauneis S; Forneris A; Pacifici R; Marinelli E; Kyriakou C; Pichini S; Busardò FP
Clin Chem Lab Med; 2017 Aug; 55(9):1324-1331. PubMed ID: 28080998
[TBL] [Abstract][Full Text] [Related]
19. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone concentrations in the central nervous system and cerebrospinal fluid after epidural administration to the pregnant ewe.
Kinnunen M; Kokki H; Hautajärvi H; Lantto J; Räsänen J; Voipio HM; Kokki M
Basic Clin Pharmacol Toxicol; 2019 Nov; 125(5):430-438. PubMed ID: 31222944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
